Description

Sparsentan is a potent, orally active dual endothelin angiotensin receptor antagonist (DEARA) with a unique mechanism of action. This investigational pharmaceutical compound is of significant interest for its targeted therapeutic potential in treating rare and chronic kidney diseases. It is primarily required by pharmaceutical R&D departments, contract research organizations (CROs), and manufacturers developing novel treatments for focal segmental glomerulosclerosis (FSGS) and other proteinuric glomerular diseases. We supply high-purity Sparsentan CAS NO 254740-64-2 to support critical research and development efforts worldwide.

Application

• Pharmaceutical Active Pharmaceutical Ingredient (API): Serves as the core active component in formulated drug products for clinical trials and commercial manufacturing.
• Preclinical and Clinical Research: Used in pharmacological and toxicological studies to investigate efficacy, pharmacokinetics, and safety profiles.
• Reference Standard: Employed as a high-purity qualitative and quantitative standard in analytical method development and validation (HPLC, LC-MS).
• Process Chemistry & Development: Supports route scouting, optimization, and scale-up activities for synthetic chemists.
• Mechanistic Studies: Utilized in biochemical assays to study the dual blockade of endothelin type A (ETA) and angiotensin II type 1 (AT1) receptors.

Basic Information

Product Name	Sparsentan
CAS No.	254740-64-2
Molecular Formula	C31H34ClN3O5S
Molecular Weight	596.13 g/mol
Synonyms	RE-021; BMS-346567; (2S)-2-[(4,5-dimethyl-3-isoxazolyl)methoxy]-4'-[2-methyl-4-[[(4-methyl-2-thiazolyl)sulfonyl]amino]phenoxy]-α,α-dimethyl-1,1'-biphenyl-2-acetic acid; 1,1'-Biphenyl-2-acetic acid, α,α-dimethyl-2-[(4,5-dimethyl-3-isoxazolyl)methoxy]-4'-[2-methyl-4-[[(4-methyl-2-thiazolyl)sulfonyl]amino]phenoxy]-, (αS)-; Sparsentanum; UNII-4KZ6R8P61L
EINECS	Contact for details

Quality Control

Our Sparsentan is manufactured under strict quality management systems. Each batch undergoes comprehensive analytical testing to ensure identity, purity, and consistency, meeting the stringent requirements for pharmaceutical research. A detailed Certificate of Analysis (COA) is provided with every shipment, documenting critical parameters including assay, related substances, residual solvents, and heavy metals. We support compliance with ICH Q7 guidelines and relevant pharmacopeial standards.

Storage

Preserve in a tightly closed container, protected from light. Store in a cool, dry place at a controlled room temperature (15-25°C). This product is hygroscopic (moisture-sensitive) and should be handled under dry conditions to maintain stability and purity.

Specification

Item	Specification
Appearance	White to off-white solid
Identification (IR)	Conforms to reference spectrum
Identification (HPLC)	Retention time matches reference standard
Assay (HPLC)	≥98.0%
Related Substances (HPLC)	Total impurities ≤2.0% Any single impurity ≤0.5%
Residual Solvents (GC)	Complies with ICH Q3C
Heavy Metals	≤20 ppm
Loss on Drying	≤0.5%

Note: Specifications can be tailored. Please contact us for the detailed technical data sheet of a specific grade.